Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs Breeze Meds

Two GLP-1 desks, one scoreboard. We put MadeMed and Breeze Meds head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
No. 37 · Grade C

Breeze Meds

Visit Breeze Meds Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 76 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make Breeze Meds a bad call — it's best for readers starting at a low dose who want nothing charged until a provider has approved them. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
70
Supply Reliability
84
82
Transparency
94
60
Access Breadth
76
88
Clinical Oversight
84
78
Track Record
82
76
MadeMedBrief Score 86 · 76Breeze Meds

Price, coverage & the tracker

MadeMedBreeze Meds
Brief Score86/100 (B)76/100 (C)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)From $199/mo injectable · $299/mo oral (lowest dose)
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)From $399/mo injectable · $399/mo oral (lowest dose)
Coverage40 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableStableprice stable

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Breeze Meds: ⚠ Every published figure is quoted at the LOWEST dose — the funnel says higher doses may cost more, so these are floors.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.